Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 13/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319905 | 1.00 | NT5E (0.51) | NT5EPTPN1PTPN2PTPN6PTPN11 | |
| SCHEMBL3319903 | 1.00 | NT5E (0.51) | NT5EPTPN1PTPN2PTPN6PTPN11 | |
| SCHEMBL8372113 | 0.90 | NT5E (0.56) | NT5EPTPN1PTPN2PTPN6PTPN11 | |
| SCHEMBL8372110 | 0.90 | NT5E (0.56) | NT5EPTPN1PTPN2PTPN6PTPN11 | |
| SCHEMBL8331303 | 0.89 | NT5E (0.55) | NT5EPTPN1PTPN2PTPN6PTPN11 | |
| SCHEMBL8468516 | 0.89 | NT5E (0.55) | NT5EPTPN1PTPN2PTPN6PTPN11 | |
| SCHEMBL7641984 | 0.87 | NT5E (0.51) | NT5EPTPN1PTPN2PTPN6PTPN11 | |
| SCHEMBL20692018 | 0.86 | PTPN1 (0.46) | PTPN1PTPN2PTPN11LGALS3LGALS4 | |
| SCHEMBL10491971 | 0.86 | PTPN1 (0.46) | PTPN1PTPN2PTPN11LGALS3LGALS4 | |
| SCHEMBL10491974 | 0.86 | PTPN1 (0.46) | PTPN1PTPN2PTPN11LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | NT5E 226/4885PTPN1 1234/4885PTPN2 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.